In the videos below, Dr. Andrew Chi talks about ONC201 and his Phase II – Adults with Recurrent H3 K27M High-grade Glioma (NCT03295396) at NYU Langone. H3 K27M-mutant gliomas are known to overexpress DRD2, the target that ONC201 utilizes to drive its anti-cancer effects. Andrew S. Chi, MD PhD, Chief of Neuro-Oncology and the Codirector of the Brain Tumor Center at NYU Langone, is the Principal Investigator for the trial.
Content Warning: These Videos Are Intended for Doctors and Health Care Professionals.
Will Work with Distant Patients to Get Them on ONC201 Trial
NYU is 1st Actively Enrolling Site for ONC201 in Adults With Recurrent H3 K27M High-grade Glioma Trial
Patients Must Have H3 K27M Tumor Mutation for Clinical Trial with ONC201
ONC201 is Taken Orally with Minimal Side Effects
Patients Must Have Progressive Disease after 1st Line of Therapy to Enroll in ONC201 Trial
Phase 2 Clinical Trial of ONC201 in Patients with Glioma that has H3 K27M Mutation
K27M Mutations are Rare within Gliomas, an Already Rare Cancer Type
ONC201 has Selectivity Anti-Cancer Properties and is a Dopamine Receptor D2 Antagonist